CD24 has been identified to be up-regulated in various solid tumors, such as breast cancer[2], prostate cancer[3] and cholangiocarcinoma[4], and its overexpression is usually associated with poor clinical outcomes in some tumor types[2-4]. This evidence concerns the gene CD24 and breast carcinoma.